Clinical Trial Update: Aflibercept 8 mg for nAMD: Early Anatomical and Functional Changes

View source ↗

Summary

This clinical trial update reports early anatomical and functional changes observed with aflibercept 8 mg for neovascular age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Federico II University | Conditions: Presence of Retinal Fluid, Changes in Macular Pigment Optical Density | Status: COMPLETED